Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2014

01.05.2014 | short review

Follow-up in aggressive lymphomas

verfasst von: MD Prof. Dr. Jan Walewski

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

A number of important contributions to the clinical knowledge of aggressive B-cell lymphoma were published over the past year. Among potential practice-changing studies—or those preventing unjustified change, were studies on improved risk classification, dose-dense immunochemotherapy, early autologous stem-cell transplantation, and the first clinical report on the use of immune checkpoint blockade to improve outcome of high-dose therapy.
Literatur
1.
Zurück zum Zitat Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42. Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.
2.
Zurück zum Zitat Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diff use large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensifi cation with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diff use large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensifi cation with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26.
3.
Zurück zum Zitat Pfreundschuh M, Schubert J, Ziepert M, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Anthony H German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16. Pfreundschuh M, Schubert J, Ziepert M, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Anthony H German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.
4.
Zurück zum Zitat Delarue R, Tilly H, Salles GA, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): final analysis of the LNH03-6B GELA study. J Clin Oncol. 2012;30:8021 (abstr). Delarue R, Tilly H, Salles GA, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): final analysis of the LNH03-6B GELA study. J Clin Oncol. 2012;30:8021 (abstr).
5.
Zurück zum Zitat Pfreundschuh M, Trumper L, Osterborg A, et al. MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91. Pfreundschuh M, Trumper L, Osterborg A, et al. MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
6.
Zurück zum Zitat Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma (LNH03–2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–67. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma (LNH03–2B): an open-label randomised phase 3 trial. Lancet. 2011;378:1858–67.
7.
Zurück zum Zitat Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369:1681–90. Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369:1681–90.
8.
Zurück zum Zitat Schmitz N, Nickelsen M, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002–1). Lancet Oncol. 2012;13:1250–59. Schmitz N, Nickelsen M, Ziepert M, et al. German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002–1). Lancet Oncol. 2012;13:1250–59.
9.
Zurück zum Zitat Jacobsen ED. Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:4268–70. Jacobsen ED. Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol. 2013;31:4268–70.
10.
Zurück zum Zitat Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013;31:4199–206.
Metadaten
Titel
Follow-up in aggressive lymphomas
verfasst von
MD Prof. Dr. Jan Walewski
Publikationsdatum
01.05.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0141-0